BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

  March 31, 2026

   · 

  4 min read
• Press Releases

  Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients

  March 31, 2026

   · 

  2 min read
• 

  Mergers & acquisitions

  Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda

  In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.

  March 31, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

  March 31, 2026

   · 

  6 min read
• Press Releases

  Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

  March 31, 2026

   · 

  8 min read
• Press Releases

  Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1

  March 31, 2026

   · 

  3 min read
• Press Releases

  PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

  March 31, 2026

   · 

  5 min read
• Press Releases

  Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

  March 31, 2026

   · 

  5 min read
• Press Releases

  Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

  March 31, 2026

   · 

  6 min read
• Press Releases

  Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

  March 31, 2026

   · 

  10 min read